Please provide your email address to receive an email when new articles are posted on . Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...
The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...
The BLA is based on LEQEMBI subcutaneous (SC) sub-studies of the Phase 3 Clarity AD open-label extension (OLE) trial in individuals with early AD, which evaluated a range of subcutaneous doses. Data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback